Indivior PLC (FRA:2IVB)
€ 9.8 0.2 (2.08%) Market Cap: 1.21 Bil Enterprise Value: 1.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 63/100

Indivior PLC at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 16, 2022 / 12:20PM GMT
Release Date Price: €16.8 (-1.41%)
Graham Glyn Charles Parry
BofA Securities, Research Division - MD and Head of Healthcare Equity Research

So thanks for staying with us after lunch. And as we sort of draw to the close of the presentations, it's my pleasure to be able to introduce Indivior. So some of you may be familiar with Indivior. But Mark Crossley is the CEO, and he is going to run through a presentation, just on the company opportunities in their opioid use disorder markets, and then we will open up for Q&A. So Mark, pleasure to have you here in London. The podium is all yours.

Mark Crossley
Indivior PLC - CEO & Executive Director

Thanks, Graham. Really appreciate it. Yes. Thanks again, Graham. And great to be here back in person. It seems like it's becoming more normal. I'll bypass the forward-looking statements, assuming everyone's read them. And let's just start with why Indivior. And I think the key here for those that don't know Indivior is we are the leaders in addiction. We're pioneering life-transforming treatments for both addiction and serious mental illness, where

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot